# NeOnc Technologies Holdings, Inc > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/NeOnc Technologies Holdings, Inc). ## Overview NEONC TECHNOLOGIES HOLDINGS, INC. is a U.S.-based clinical-stage biopharmaceutical company developing therapies for malignant brain cancers. Its lead program, NEO100, is being tested as an intranasal treatment in Phase 2a, while NEO212 and other candidates remain in preclinical or early clinical development. ## Products & services • NEO100 intranasal therapy for malignant glioma • NEO212 preclinical/early clinical brain cancer candidate • Additional oncology drug candidates in preclinical development • Humanitarian “right to try” patient access fees - **Lead clinical candidate: NEO100** (70%) — Intranasal therapy being evaluated in Phase 1 and Phase 2a studies for malignant glioma and related brain tumors. - **Pipeline candidate: NEO212** (20%) — Second oncology candidate that has completed preclinical testing and entered early clinical development. - **Preclinical pipeline** (5%) — Additional drug candidates under discovery and preclinical development for future oncology indications. - **Humanitarian access fees** (5%) — Occasional fees received from patients under a right-to-try humanitarian program. - NEO100 intranasal therapy for recurrent malignant glioma - NEO212 brain cancer candidate with IND accepted by FDA - Additional preclinical oncology drug candidates - Humanitarian right-to-try access program ## Customers The company’s direct end users are patients with malignant brain cancers, especially recurrent glioma and other primary or secondary malignant brain tumors. Commercially, any future sales would depend on oncologists, hospitals, and third-party payors that decide whether the therapy is clinically useful, covered, and reimbursable. Until approval and commercialization, the company’s “customers” are largely clinical investigators, trial sites, and potential licensing or commercialization partners. - **Brain cancer patients** (primary) — Patients with recurrent or primary malignant brain tumors who may receive NEO100 or NEO212 in trials or future approved use. - **Clinical investigators and trial sites** (primary) — Hospitals, physicians, and research centers that enroll patients and generate the safety/efficacy data needed for approval. - **Third-party payors** (primary) — Insurers and reimbursement bodies that would determine whether approved products are covered and economically viable. - **Commercial partners** (secondary) — Pharma or biotech partners that could license, market, or distribute products in foreign markets. - Patients with recurrent malignant glioma seeking investigational treatment - Oncologists and neuro-oncology centers running clinical trials - Hospitals and treatment centers that would adopt approved therapies - Third-party payors whose coverage determines commercial uptake - Potential pharma/biotech partners for ex-U.S. commercialization ## Geography The company is headquartered in the United States and its development work is centered on U.S. regulatory pathways, including FDA review of NEO212. Management also contemplates partnering or licensing in foreign markets if products are approved, but no country-level revenue concentration is disclosed because the company has not generated meaningful product sales. Geography currently matters more as a regulatory and commercialization issue than as a revenue driver. - United States is the core operating and regulatory base - FDA approval is central to the lead and pipeline programs - Potential foreign partnerships are part of future commercialization - No meaningful country revenue disclosure is available - Current exposure is mainly U.S. clinical and regulatory execution ## Strategy The company’s strategy is to advance NEO100 and NEO212 through clinical development, secure regulatory approval, and then decide whether to commercialize directly or through partners. Because it has no approved products, the near-term focus is funding, trial execution, manufacturing readiness, and intellectual property protection rather than sales expansion. - **Clinical development of NEO100** (short-term) — The lead asset must show safety and efficacy before any commercial value can be realized. - **Advance NEO212 and pipeline assets** (medium-term) — A broader pipeline increases the chance of eventual approval and reduces single-asset dependence. - **Secure financing and partnerships** (short-term) — The company needs external capital and may need collaborators to fund development and commercialization. - Advance NEO100 through Phase 2a efficacy testing - Move NEO212 through early clinical development - Secure additional capital to fund trials and operations - Protect patents, trade secrets, and regulatory exclusivity - Use partnerships or licensing for future commercialization ## Risks NEONC is a pre-revenue biotech with substantial going-concern and financing risk, so its ability to continue operations depends on raising capital and advancing clinical programs. Its commercial opportunity also depends on regulatory approval, manufacturing execution, reimbursement, and competition from better-funded oncology developers. Because it relies on third parties for research, manufacturing, and potential commercialization, operational setbacks can directly delay or eliminate value creation. - **Going concern and funding shortfall** [critical] — The company has substantial losses, limited revenue, and needs external capital to fund trials and operations. - **Clinical and regulatory failure** [critical] — NEO100 and NEO212 must prove safety and efficacy and obtain FDA approval before generating meaningful revenue. - **Manufacturing and third-party reliance** [high] — The company relies on external parties for ingredients, testing, and manufacturing support. - **Commercialization and reimbursement risk** [high] — Even if approved, uptake depends on payor coverage, physician adoption, and market access. - **Competitive pressure** [high] — Larger biopharma and biotech firms may develop safer or more effective therapies faster. - Going-concern risk and continued operating losses - Need for additional capital could force dilution or program cuts - Clinical and regulatory failure could eliminate product value - Manufacturing and third-party supply dependence can delay approval - Competition may reach market faster or with better efficacy - Reimbursement and payor coverage may limit uptake after approval ## Accounting The most important accounting issue is stock-based compensation, which depends on grant-date fair value, vesting assumptions, and forfeiture estimates and can materially affect operating expenses. The company also has limited revenue, with occasional humanitarian right-to-try fees that are not part of core operations, so period-to-period comparability is driven mainly by R&D, legal, and G&A spending rather than sales. Investors should also watch financing-related accounting, including related-party advances, equity issuances, and any future debt or collaboration arrangements. - **Stock-based compensation** — Can materially change reported loss and quarterly comparability - **Non-core humanitarian revenue** — Revenue is not representative of commercial traction - **Going-concern assessment** — Signals uncertainty around continuation of operations - **Related-party financing** — Can influence leverage, ownership, and cash runway - Stock-based compensation can materially move reported expenses - Forfeiture and performance assumptions affect RSU expense timing - Right-to-try fees are non-core and not a stable revenue base - Related-party advances and equity raises affect capital structure - Going-concern disclosures signal judgment around liquidity assumptions --- *Last updated: 2026-09-24T11:50:17.890852+00:00*